SpringWorks Therapeutics, Inc. (SWTX)
| Market Cap | 3.26B |
| Revenue (ttm) | 5.45M |
| Net Income (ttm) | -325.10M |
| Shares Out | 73.79M |
| EPS (ttm) | -5.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 977,944 |
| Open | 42.59 |
| Previous Close | 43.38 |
| Day's Range | 41.75 - 45.20 |
| 52-Week Range | 18.00 - 53.92 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 66.60 (+50.68%) |
| Earnings Date | May 2, 2024 |
About SWTX
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SWTX stock is "Strong Buy." The 12-month stock price forecast is $66.6, which is an increase of 50.68% from the latest price.
News
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors al...
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ...
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced to...
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 –
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present ...
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced tod...
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced tod...
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced tod...
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...
SpringWorks Therapeutics Shares Skyrocket on FDA Approval of Desmoid Tumor Drug
Shares of SpringWorks Therapeutics (SWTX) soared over 18% Tuesday after the Food and Drug Administration (FDA) gave its approval for the use of its pill to treat adults with non-cancerous growths in t...
SpringWorks Therapeutics' stock jumps after FDA approves first treatment for rare type of aggressive tumors
SpringWorks Therapeutics Inc. shares SWTX jumped more than 9% premarket on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of non-cancerous but aggres...
As the SpringWorks (SWTX) stock price surges, is it a good buy?
SpringWorks Therapeutics (NASDAQ: SWTX) stock price bounced back in the overnight session after major developments in the company. The shares jumped by over 16% to $24.10, which was much higher than i...
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain,...
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment
The U.S. health regulator on Monday approved SpringWorks Therapeutics' drug for treating adult patients with desmoid tumors, making it the first approved treatment for this type of non-cancerous soft-...
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review –
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
– PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 –
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
- Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools -
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment –
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients ...
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc's tumor treatment by three months as the health regulator needs more time to review additional da...